A case of disseminated M. bovis bacillus Calmette-Guérin (BCG) disease after one month of BCG bladder infusion therapy and analysis of 77 cases of suspected BCG infection in Japan, 2017–2022

Respiratory Medicine Case Reports - Tập 45 - Trang 101902 - 2023
Masashi Nishimura1,2, Masao Okumura1, Takemasa Takii3, Takashi Yoshiyama1, Yoshiaki Tanaka1, Mikio Saotome1, Ken Ohta1
1Respiratory Disease Center, Fukujuji Hospital, Japan Anti-Tuberculosis Association, Japan
2Division of Infectious Diseases and Respiratory Medicine, Department of Internal Medicine, National Defense Medical College, Japan
3Department of Mycobacterium Reference and Research, Research Institute of Tuberculosis, Japan Anti-Tuberculosis Association, Japan

Tài liệu tham khảo

Guallar-Garrido, 2020, Bacillus calmette-guérin (BCG) therapy for bladder cancer: an update, ImmunoTargets Ther., 9, 1, 10.2147/ITT.S202006

Asín, 2014, Bacillus Calmette-Guérin (BCG) infection following intravesical bcg administration as adjunctive therapy for bladder cancer incidence, risk factors, and outcome in a single-institution series and review of the literature, Méd., 93, 236

Gandhi, 2013, Bacillus Calmette-Guérin immunotherapy for genitourinary cancer, BJU Int., 112, 288, 10.1111/j.1464-410X.2012.11754.x

Lamm, 1992, Incidence and treatment of complications of bacillus Calmette-Guerin intravesical therapy in superficial bladder cancer, J. Urol., 147, 596, 10.1016/S0022-5347(17)37316-0

Grange, 2001, Mycobacterium bovis infection in human beings, Tuberculosis, 81, 71, 10.1054/tube.2000.0263

Gandhi, 2013, Bacillus Calmette-Guérin immunotherapy for genitourinary cancer, BJU Int., 112, 288, 10.1111/j.1464-410X.2012.11754.x

Talbot, 1997, PCR identification of Mycobacterium bovis BCG, J. Clin. Microbiol., 35, 566, 10.1128/jcm.35.3.566-569.1997

Ueyama, 2014, Sub-speciation of Mycobacterium tuberculosis complex from tuberculosis patients in Japan, Tuberculosis, 94, 15, 10.1016/j.tube.2013.09.006

Brossman, 1982, Experience with bacillus Calmette-Guerin in patients with superficial bladder carcinoma, J. Urol., 128, 27, 10.1016/S0022-5347(17)52736-6

Brausi, 2014, Side effects of bacillus calmette-guérin (BCG) in the treatment of intermediate- and high-risk Ta, T1 papillary carcinoma of the bladder: results of the EORTC genito-urinary cancers group randomised phase 3 study comparing one-third dose with full dose an, Eur. Urol., 65, 69, 10.1016/j.eururo.2013.07.021

Lamm, 2000, Efficacy and safety of bacille Calmette-Guérin immunotherapy in superficial bladder cancer, Clin. Infect. Dis., 31, 86, 10.1086/314064

Graham, 1994, Efficacy of BCG vaccine in the prevention of tuberculosis meta-analysis of the published literature, JAMA, 271, 698, 10.1001/jama.1994.03510330076038

Gonzalez-Perez, 2021, The BCG vaccine for COVID-19: first verdict and future directions, Front. Immunol., 12

1984, WHO: expanded programme on immunization (EPI) indications and contraindications for vaccines used in the EPI, Wkly. Epidemiol. Rec., 59, 13

Bowyer, 1995, The persistence of bacille Calmette‐Guerin in the bladder after intravesical treatment for bladder cancer, Br. J. Urol., 75, 188, 10.1111/j.1464-410X.1995.tb07309.x

Andreas, 2003, Immune mechanisms in bacillus Calmette-Guerin immunotherapy for superficial bladder cancer, J. Urol., 170, 964, 10.1097/01.ju.0000073852.24341.4a

María, 2014, Bacillus Calmette-Guérin (BCG) infection following intravesical BCG administration as adjunctive therapy for bladder cancer: incidence, risk factors, and outcome in a single-institution series and review of the literature, Medicine (Baltim.), 93, 236, 10.1097/MD.0000000000000119

Martin, 1993, 22, 1352

Elkabani, 2000, Disseminated Mycobacterium bovis after intravesicular bacillus Calmette-Guerin treatments for bladder cancer, Cancer Control, 7, 476, 10.1177/107327480000700512

2003, The treatment of tuberculosis, CDC, 52

Thông tin
Thông tin xuất bản

Respiratory Medicine Case Reports

Tập 45

101902

Thông tin tác giả